Emerging cellular therapies continue to generate significant interest and activity in medical research. They represent possible new treatment avenues that could completely shift how cancer is treated – if the research bears out this potential. Baylor Scott & White Research Institute (BSWRI) is working to accelerate the progression of these types of clinical trials with its good manufacturing practices (cGMP) Core lab in Dallas, TX, which produces human cellular products for phase I clinical trials. It is a resource and facility unique to the program in North Texas, and one that has enabled BSWRI to deliver access to unique cellular therapy clinical trials to patients across the region.

Read more